A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 May 2017
At a glance
- Drugs Insulin degludec/liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 25 Apr 2017 Planned End Date changed from 15 Apr 2019 to 16 Aug 2019.
- 25 Apr 2017 Planned initiation date changed from 15 Apr 2017 to 16 Aug 2017.
- 29 Mar 2017 Planned End Date changed from 1 Mar 2019 to 15 Apr 2019.